A pharmaceutical composition for use in a method of treatment or repair of a lesion in the infarct zone in a revascularized subject after an acute myocardial infarction (AMI), where the infarction zone lesion comprises adverse ventricular remodeling, comprising The composition: (a) an amount of perfusion improvement of the infarct zone of a product of sterile non-expanded chemotactic isolated hematopoietic stem cells, the product comprising an enriched population of at least 10 x 106 isolated autologous CD34 + stem cells that contain a subpopulation of at least 0.5 x 106 potent CD34 + / CXCR-4 + cells that have SDF-1 / CXCR-4 mediated migratory activity； (b) a stabilizing amount of serum at a concentration of at least 10% (v / v)； and (c) optionally a therapeutically effective amount of at least one compatible agent that stimulates the growth of cardiomyocytes； where the enriched population of isolated CD34 + cells, when passed through a catheter and analyzed in vitro, comprises at least 70% of CD34 + cells； and where the enriched population of isolated CD34 + cells, when passed through a catheter and analyzed in vitro: (1) retains the migration activity mediated by SDF-1 / CXCR-4； (2) has a viability of at least 70%； and (3) is capable of forming hematopoietic colonies in vitro for at least 24 hours after the acquisition of the subject of the enriched population of CD34 + cells； and where the composition is administered to the subject parenterally through a catheter.Una composición farmacéutica para su uso en un método de tratamiento o reparación de una lesión en la zona de infarto en un sujeto revascularizado después de un infarto agudo de miocardio (IAM), donde la lesión de la zona de infarto comprende remodelado ventricular adverso, comprendiendo la composición: (a) una cantidad de mejora de la perfusión de la zona del infarto de un producto de células madre hematopoyéticas quimiotácticas aisladas estériles no expandidas, comprendiendo el producto una población
